Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAF<sup>V600E</sup>-Mutated Thyroid Cancer
Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose BRAF mutations are detected in 30%-80% of papillary thyroid cancer (PTC) cases. Dabrafenib and trametinib showed promising antitumor activity in patients with BRAFV600E-mutated metastatic melanoma and non–small cell lung cancer. This study aimed to evaluate the efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer. Materials and Methods This was a retrospective study to evaluate the efficacy of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated PTC. The patients received dabrafenib 150 mg twice daily and trametinib 2 mg once daily at the Samsung Medical Center. This study evaluated the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) overall survival (OS), and safety of dabrafenib and trametinib. Results Between December 2019 and January 2022, 27 PTC patients including eight patients with poorly differentiated or anaplastic transformation, received dabrafenib and trametinib. The median age was 73.0 years, and the median follow-up period was 19.8 months. The majority (81.5%) had undergone thyroidectomy, while 8 patients had received prior systemic treatments. ORR was 73.1%, with 19 partial responses, and DCR was 92.3%. Median PFS was 21.7 months, and median OS was 21.7 months. Treatment-related adverse events included generalized weakness (29.6%), fever (25.9%), and gastrointestinal problems (22.2%). Dose reduction due to adverse events was required in 81.5% of the patients. Conclusion Dabrafenib and trametinib demonstrated a high ORR with promising PFS; however, most patients with BRAFV600E-mutated metastatic PTC required a dose reduction.
Abstract
Purpose BRAF mutations are detected in 30%-80% of papillary thyroid cancer (PTC) cases. Dabrafenib and trametinib showed promising antitumor activity in patients with BRAFV600E-mutated metastatic melanoma and non–small cell lung cancer. This study aimed to evaluate the efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer. Materials and Methods This was a retrospective study to evaluate the efficacy of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated PTC. The patients received dabrafenib 150 mg twice daily and trametinib 2 mg once daily at the Samsung Medical Center. This study evaluated the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) overall survival (OS), and safety of dabrafenib and trametinib. Results Between December 2019 and January 2022, 27 PTC patients including eight patients with poorly differentiated or anaplastic transformation, received dabrafenib and trametinib. The median age was 73.0 years, and the median follow-up period was 19.8 months. The majority (81.5%) had undergone thyroidectomy, while 8 patients had received prior systemic treatments. ORR was 73.1%, with 19 partial responses, and DCR was 92.3%. Median PFS was 21.7 months, and median OS was 21.7 months. Treatment-related adverse events included generalized weakness (29.6%), fever (25.9%), and gastrointestinal problems (22.2%). Dose reduction due to adverse events was required in 81.5% of the patients. Conclusion Dabrafenib and trametinib demonstrated a high ORR with promising PFS; however, most patients with BRAFV600E-mutated metastatic PTC required a dose reduction.
참고문헌 (26)
- Miranda-Filho A, "Thyroid cancer incidence trends by histology in 25 countries : a population-based study", Lancet Diabetes Endocrinol, 9, pp.225~234 (2021)
- Kim J, "Geographic influences in the global rise of thyroid cancer", Nat Rev Endocrinol, 16, pp.17~29 (2020)
- Sherman SI, "Thyroid carcinoma", Lancet, 361, pp.501~511 (2003)
- "SEER cancer statistics review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site" (2018)[URL]
- Brito JP, "Low risk papillary thyroid cancer", BMJ, 348, pp.g3045~ (2014)
- Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer", Am J Med, 97, pp.418~428 (1994)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer", Thyroid, 26, pp.1~133 (2016)
- "Thyroid carcinoma (version 3.2022)" (2023)[URL]
- Ragazzi M, "Update on anaplastic thyroid carcinoma : morphological, molecular, and genetic features of the most aggressive thyroid cancer", Int J Endocrinol, 2014, pp.790834~ (2014)
- Fagin JA, "Biologic and clinical perspectives on thyroid cancer", N Engl J Med, 375, pp.1054~1067 (2016)
- Saini S, "Therapeutic advances in anaplastic thyroid cancer : a current perspective", Mol Cancer, 17, pp.154~ (2018)
- Baloch ZW, "Overview of the 2022 WHO classification of thyroid neoplasms", Endocr Pathol, 33, pp.27~63 (2022)
- Schlumberger M, "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer", N Engl J Med, 372, pp.621~630 (2015)
- Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer : a randomised, double-blind, phase 3 trial", Lancet, 384, pp.319~328 (2014)
- Landa I, "Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers", J Clin Invest, 126, pp.1052~1066 (2016)
- Peyssonnaux C, "The Raf", MEK, Biol Cell, pp.2001, 93[DOI]
- Liu D, "BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells", J Clin Endocrinol Metab, 92, pp.2264~2271 (2007)
- King AJ, "Dabrafenib; preclinical characterization, increa-sed efficacy when combined with trametinib, while BRAF", MEK tool combination reduced skin lesions, 2013, pp.8, e67583~
- Kim KB, "Phase II study of the MEK1", MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor, 2013, pp.31, 482~489
- Long GV, "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma", N Engl J Med, 371, pp.1877~1888 (2014)
- Long GV, "Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma : a multicentre, double-blind, phase 3 randomised controlled trial", Lancet, 386, pp.444~451 (2015)
- Planchard D, "Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer : an open-label, phase 2 trial", Lancet Oncol, 18, pp.1307~1316 (2017)
- Planchard D, "Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC : updated 5-year survival rates and genomic analysis", J Thorac Oncol, 17, pp.103~115 (2022)
- Subbiah V, "Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer", J Clin Oncol, 36, pp.7~13 (2018)
- Subbiah V, "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer : updated analysis from the phase II ROAR basket study", Ann Oncol, 33, pp.406~415 (2022)
- Busaidy NL, "Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer : results of a randomized, phase 2, open-label multicenter trial", Thyroid, 32, pp.1184~1192 (2022)